<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168219</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02053</org_study_id>
    <secondary_id>NCI-2011-02053</secondary_id>
    <secondary_id>CALGB-100801</secondary_id>
    <secondary_id>CDR0000681025</secondary_id>
    <secondary_id>CALGB 100801</secondary_id>
    <secondary_id>CALGB-100801</secondary_id>
    <secondary_id>U10CA180821</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT01168219</nct_id>
  </id_info>
  <brief_title>Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II clinical trial is studying how well giving busulfan, fludarabine phosphate,
      and anti-thymocyte globulin followed by donor stem cell transplant and azacitidine works in
      treating patients with high-risk myelodysplastic syndrome and older patients with acute
      myeloid leukemia. Giving low doses of chemotherapy, such as busulfan and fludarabine
      phosphate, before a donor stem cell transplant helps stop the growth of cancer cells. It
      also stops the patient's immune system from rejecting the donor's stem cells. The donated
      stem cells may replace the patient's immune cells and help destroy any remaining cancer
      cells (graft-vs-tumor effect). Sometimes the transplanted cells from a donor can also make
      an immune response against the body's normal cells. Giving anti-thymocyte globulin before
      transplant and giving azacitidine, tacrolimus, and methotrexate after the transplant may
      stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To determine if this treatment can improve 2-year progression-free survival (PFS) in
      patients with high risk myelodysplastic syndrome (MDS) and in patients with acute myeloid
      leukemia (AML) &gt;= 60 yrs age

      SECONDARY OBJECTIVES:

      I. To determine the safety and feasibility of using post-transplantation azacitidine.

      II. To determine the ability to use pharmacokinetic-directed busulfan to achieve area under
      the curve (AUC) within 20% of target AUC in &gt; 80% of patients.

      III. To determine the rate of grade II-IV and III-IV acute graft-vs-host disease (GVHD).

      IV. To determine the incidence of extensive chronic GVHD. V. To determine treatment-related
      mortality at 100 days and at 1 year. VI. To determine 5-year overall survival.

      OUTLINE:

      REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate intravenously (IV)
      over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and
      anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor [MSD]) or
      -6 to -4 (matched unrelated donor [MUD]).

      TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day
      0 or on days 0-1.

      GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus orally (PO) or IV on days -2
      to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6
      (MSD), and 11 (MUD).

      CONSOLIDATION: Beginning on day 42, patients receive azacitidine subcutaneously (SC) or IV
      on days 1-5.

      Treatment repeats every 4 weeks for 6 courses. Blood and bone marrow samples may be
      collected periodically for correlative and pharmacokinetic studies.

      After completion of study treatment, patients are followed up every 6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At 2 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier product limit estimator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier product limit estimator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality (TRM)</measure>
    <time_frame>Up to 6 months post-treatment</time_frame>
    <description>TRM is defined as death within the first six months after transplant not secondary to relapse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Adult Acute Megakaryoblastic Leukemia</condition>
  <condition>Adult Acute Monoblastic Leukemia</condition>
  <condition>Adult Acute Monocytic Leukemia</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With Maturation</condition>
  <condition>Adult Acute Myeloid Leukemia With Minimal Differentiation</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1</condition>
  <condition>Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A</condition>
  <condition>Adult Acute Myeloid Leukemia Without Maturation</condition>
  <condition>Adult Acute Myelomonocytic Leukemia</condition>
  <condition>Adult Erythroleukemia</condition>
  <condition>Adult Pure Erythroid Leukemia</condition>
  <condition>Alkylating Agent-Related Acute Myeloid Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndrome</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor [MSD]) or -6 to -4 (matched unrelated donor [MUD]).
TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0 or on days 0-1.
GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus PO or IV on days -2 to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6 (MSD), and 11 (MUD).
CONSOLIDATION: Beginning on day 42, patients receive azacitidine SC or IV on days 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic hematopoietic stem cell transplantation</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given SC or IV</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (chemotherapy and transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets one of the following sets of criteria:

               -  Myelodysplastic syndromes (MDS):

                    -  Disease with high-risk features (found either at diagnosis or before
                       initiation of cytotoxic therapy), defined as one of the following:

                         -  International prognostic scoring system (IPSS) risk &gt;= intermediate-2

                         -  Refractory anemia with excess blasts by French-American-British (FAB)
                            classification

                         -  High-risk cytogenetics (either complex or -7)

                    -  Less than 10% bone marrow blasts as determined by bone marrow biopsy within
                       the past 4 weeks (reduction in marrow blast percentage may be achieved with
                       chemotherapy or other therapy)

                    -  Less than 75 years old

               -  Acute myeloid leukemia (AML):

                    -  No FAB M3

                    -  No acute leukemia following blast transformation of prior chronic
                       myelogenous leukemia or other myeloproliferative disease

                    -  Patients with preceding MDS or treatment-related AML are eligible

                    -  Prior central nervous system (CNS) involvement is allowed provided the
                       disease is in remission at transplantation

                    -  Morphologic complete remission (leukemia-free state) is defined as meeting
                       all of the following criteria:

                         -  Bone marrow blasts &lt; 5% (as determined by bone marrow within the past
                            4 weeks), but without requirement for normal peripheral blood counts

                         -  No extramedullary leukemia

                         -  No blasts in peripheral blood

                    -  Achieved complete remission (CR) after no more than 2 courses of induction
                       chemotherapy

                         -  Patients treated with azacitidine or decitabine who achieve a
                            leukemia-free state are eligible (may have required up to 4 courses of
                            therapy to reach this status)

                    -  Age 60 to 74 years

          -  Donors must meet the following criteria:

               -  One of the following:

                    -  HLA-identical sibling (6/6) by serologic typing for class (A, B) and
                       low-resolution molecular typing for class II (DRB1)

                    -  Matched unrelated donor (8/8) by high-resolution molecular typing at HLA-A,
                       -B, -C, and DRB1

               -  No syngeneic donors

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Calculated creatinine clearance â‰¥ 40 mL/min

          -  Bilirubin &lt; 2 mg/dL OR bilirubin 2-3 mg/dL provided direct bilirubin is normal

          -  Aspartate aminotransferase (AST) &lt; 3 times upper limit of normal

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &gt; 40% with no symptomatic
             pulmonary disease

          -  Left ventricle ejection fraction (LVEF) &gt;= 30% by echocardiogram (ECHO) or multigated
             acquisition (MUGA)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No uncontrolled diabetes mellitus or active serious infections

          -  No known hypersensitivity to E. coli-derived products, azacitidine, or mannitol

          -  No human immunodeficiency virus (HIV) infection or active hepatitis B or C

          -  Prior azacitidine or decitabine allowed

               -  No patients who progressed from MDS to AML during treatment with azacitidine or
                  decitabine

          -  At least 4 weeks since prior deoxyribonucleic acid (DNA)-hypomethylating
             chemotherapy, radiotherapy, and/or surgery

          -  No more than 2 courses of consolidation therapy before transplantation (for patients
             with AML)

               -  Any consolidation regimen that does not require transplantation can be used

               -  No more than 6 months from documentation of morphologic CR to transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Vij</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alliance for Clinical Trials in Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Cecil County</name>
      <address>
        <city>Elkton</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Hospital University Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health NCORP</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>July 22, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
